Many of these compounds were originally discovered in screens with ATP-competitive inhibitor 1 0 1 libraries using oncology-associated target enzymes [32] . Protein kinases have proven to be 1 0 2 exceptional targets for the development of therapeutic agents in humans, and dozens of kinase 1 0 3 inhibitors have been approved, or will soon be approved, for cancer and anti-inflammatory indications constituting a variety of chemotypes for unbiased small molecule inhibitor discovery, which can be 1 0 7 applied to a diverse range of protein targets [34] . The analysis of carbohydrate sulphation currently relies heavily on genetic, biophysical (NMR) and 1 0 9 combinatorial organic chemistry and enzymatic analysis, with only a handful of low-affinity inhibitors 1 1 0 of carbohydrate sulphotransferases ever having been disclosed [13, 35] . More recently, a relatively 1 1 1 potent inhibitor of the related Type IV aryl sulphotransferase [36] and much lower affinity oestrogen 1 1 2 sulphotransferases inhibitors [37] [38] [39] were reported. Due to a lack of any selective chemical tool 1 1 3 compounds, cellular glycan sulphation remains highly understudied, relying on non-specific cellular 1 1 4 methods such as chlorate exposure [40] , and the field remains ripe for technological innovation and 1 1 5 new chemical biology approaches. Early attempts to discover such molecules amongst small, inhibitor [35] . This raises the question as to whether PAPS-dependent sulphotransferases are general 1 1 9 inhibitory targets for new or repurposed small molecules that target nucleotide-binding sites, 1 2 0 especially broader families of compounds originally developed as protein kinase inhibitors. However, Figure 1E ). Consistently, PAPS did not stabilise the catalytic We next analysed the sensitivity of this assay for measuring HS2ST stability shifts over a wide range 2 7 6 of PAPS concentrations, which confirmed dose-dependent stabilisation of recombinant HS2ST by 2 7 7 PAPS, with detection of binding in the low micromolar range of the co-factor, equivalent to a molar 2 7 8 ratio of ~1:1 HS2ST:PAPS (Supplementary Figure 1A) . Subsequently, we explored the potential of 2 7 9 this assay to detect binding of a putative IdoA-containing oligosaccharide substrate for HS2ST, 2 8 0 confirming dose-dependent effects of this polymeric glycan over a range of concentrations, consistent 2 8 1 with binding and conformational stability. Similar to PAPS, detection of binding was observed in the 2 8 2 low micromolar range, equivalent to a molar ratio of ~1:1 HS2ST:glycan (Supplementary Figure 1B) .
8 3
We also evaluated binding of a panel of adenine-based cofactors (PAP and ATP), which suggested inducing a ΔΤm of ~3°C, similar to that observed with the HS2ST co-factor PAPS. In contrast, 2 8 6 removal of the sulpho moiety of PAPS, which creates the enzymatic end product PAP, was not 2 8 7 deleterious to HS2ST binding ( Supplementary Figure 2A) , consistent with structural analysis of the 1 factor APS, in which the 3'-phosphate group of adenine is absent, did not induce HS2ST stabilisation, 2 9 1 confirming a requirement for this charged modification ( Supplementary Figure 2A ). We also 2 9 2 established that CoA and acetyl CoA, which both contain a 3'-phosphoadenine moiety, clearly 2 9 3 induced thermal stabilisation of HS2ST; loss of the 3'-phosphate group in dephospho CoA abolished 2 9 4 this effect ( Supplementary Figure 2A) . Finally, we demonstrated that ATP, GTP and ADP, but not 2 9 5 AMP or cAMP, were all effective at protecting HS2ST from thermal denaturation, suggesting that 2 9 6 they are also HS2ST ligands ( Supplementary Figure 2A) . To extend our HS2ST thermal analysis to identify potential glycan substrates, we evaluated enzyme 2 9 9 stability in the presence of synthetic glycan chains of different lengths and sulphation patterns ( Table   3 0 0 1). Of particular interest for further assay development, thermal shift (stabilisation) was detected in 3 0 1 this assay when hexasaccharide (dp6) or a higher degree of polymerisation oligosaccharide was 3 0 2 incubated with the enzyme (Supplementary Figure 2B ), suggesting that a dp6 glycan might represent 3 0 3 the shortest potential partner suitable for HS2ST binding, a prerequisite for enzymatic modification. Interestingly, highly sulphated hexameric glycans served as efficient HS2ST binding partners relative 3 0 5 to the most highly sulphated heparin control, with a fully chemically sulphated I 2s,3s A 6s 3s Ns hexamer 3 0 6
inducing the highest HS2ST stability-shift amongst the chemically-modified derivatives assessed 3 0 7
(Supplementary Figure 2C ). Interestingly, a putative I 2OH A 6OH Ns substrate, which contains the 2-O 3 0 8 moiety predicted to be the substrate for 2-O-sulphotransferases, also led to marked thermal 3 0 9 stabilisation of HS2ST, suggestive of productive binding to HS2ST that permit it to be sulphated in 3 1 0 the presence of PAPS (Supplementary Figure 2C ).
1 1
A novel microfluidic kinetic assay to directly measure oligosaccharide sulphation by HS2ST 3 1 2
In order to quantify the effects of various ligands on HS2ST enzyme activity, we sought to develop a coupled to a linker and fluorescein at the reducing end, which interacts with HS2ST (Supplementary 3 1 8 Figure 2C ), could also be enzymatically sulphated by HS2ST using 'gold-standard' NMR-based Orange fluorescence at a similar wavelength. Instead, to confirm sulphation of the fluorescein- Next, we evaluated the incorporation of the sulphate moiety from PAPS into a fluorescently-labelled to stoichiometric conversion of the substrate into the fully sulphated product (P), which migrated very Furthermore, no sulphated product was detected in the presence of buffer or PAPS alone ( Figure 2F ), sulphation ( Figure 2G ). We also noted that high (>1 mM) concentrations of Mg 2+ ions led to 3 4 5 concentration-dependent increases in enzyme HS2ST activity ( Figure 2H ), consistent with the effects 3 4 6
of Mg 2+ ions identified in DSF assays ( Supplementary Figure 2A ). Finally, we confirmed that as previously established using DSF (Supplementary Figure 2C) . In contrast, a less highly sulphated 3 6 2 substrate was still able to compete with the fluorescent substrate in a dose-dependent manner (fixed at 3 6 3 2 μM in this assay), as indicated by the IC 50 value of <100 nM. We next compared the effects of PAP, CoA) was not ( Figure 3B ). Increasing the concentration of PAPS in the assay led to a decrease in the 3 6 8 level of inhibition by both PAP and CoA ( Figure 3C ), suggesting a PAPS-competitive mode of 3 6 9
inhibition, as predicted from the various shared chemical features of these molecules ( Figure 1A ).
Recent studies have demonstrated that PAPS-dependent tyrosyltransferases are inhibited by several 40 ± 1 nM and 123 ± 7 nM respectively ( Figure 3D ). In addition, the non-specific protein kinase 3 7 7
inhibitor rottlerin also inhibited HS2ST with an IC 50 of 6.4 μM. Increasing the concentration of PAPS inhibition for rottlerin ( Figure 3E ). The finding that the non-specific kinase inhibitor rottlerin [56] was a micromolar inhibitor of HS2ST 3 8 2 was of particular interest, especially given the remarkable progress in the development of kinase 1 4 compound using ratiometric HS2ST enzyme assays at a final compound concentration of 40 μM. We 3 9 6
reported the enzyme activity remaining compared to DMSO, with rottlerin (IC 50 = ~8 μM), suramin 3 9 7
(IC 50 = ~20 nM) and aurintricarboxylate (IC 50 = ~90 nM) as positive controls ( Figure 4B and 3 9 8
Supplementary Figures 6 and 7) . We also included the compound GW406108X in our enzyme assay, Of particular interest, these three compounds were amongst the top ~10% of compounds in terms of factor binding sites (suramin, Figure 5E ). In these binding modes, compounds make a number of 4 2 9
stabilising interactions that permit them to compete with PAPS or oligosaccharide substrate for 4 3 0 1 5 binding to HS2ST ( Figure 5C ). For example, rottlerin is predicted to form a hydrogen bond with the In this paper, we report a simple method for the detection of enzyme-catalysed glycan sulphation To facilitate rapid purification of recombinant HS2ST, the enzyme was expressed as an N-terminal 4 4 7
MBP fusion protein, and we confirmed that it was folded, and could bind to a variety of exogenous are also known to bind to their end product (ADP), and kinase structural analysis has long taken 4 5 0
advantage of the stability of kinase and ADP complexes for protein co-crystallisation. Similar co- with PAP and model saccharide substrates [20, 21] , and our study extends these approaches, by first report to demonstrate the utility of a DSF-based strategy for the analysis of a sulphotransferase. By developing a new type of rapid, kinetic glycan sulphation assay, we confirmed that many HS2ST that sulphation can be detected using a simple glycan mobility shift assay, and then quantified in real concentrations of non-radioactive co-factors, substrates and ligands in assays [58] . Consequently, we 4 7 4
were able to use this technology to derive a Km value for PAPS in our standard HS2ST assay of 1.0 4 7 5 μM ( Figure 2G ), slightly lower than the reported literature value of 18.5 μM for HS2ST using ( Supplementary Figure 4) In the future, it might be possible to quantify other site-specific covalent modifications in complex Our finding that HS2ST was inhibited at sub-micromolar concentrations by the compounds suramin 4 9 7
[67] and the DNA polymerase inhibitor aurintricarboxylic acid [68] was intriguing, and consistent 4 9 8
with recent reports demonstrating inhibitory activity of these compounds towards tyrosyl protein 4 9 9
sulphotransferases, which employ PAPS as a co-factor, but instead sulphate tyrosine residues in wide variety of biological effects likely due to its non-specific inhibition of multiple protein kinases 5 0 6
[56]. This lack of specificity prevents exploitation of rottlerin in cells as a specific probe, although our 5 0 7
finding that HS2ST is a target of this compound opens up the possibility that this, or other, protein target the PAPS or oligosaccharide-binding sites in the enzyme. To evaluate these possibilities further, 5 1 0
we screened PKIS, a collection of drug-like molecules with broad inhibitory activity towards multiple 5 1 1 protein kinases. Interestingly, only 3 compounds (<1% of the library) consistently showed marked 5 1 2 inhibitory activity at 40 μM in our HS2ST enzyme assay ( Figure 4A, B and C, red) . Remarkably, all 5 1 3 three compounds belonged to the same benzylidene-1H-inol-2-one (oxindole) chemical class, which 5 1 4
were originally reported as potent ATP-dependent RAF kinase inhibitors that block the MAPK 5 1 5 signalling pathway in cultured cells [70] . Retrospectively, of all the related chemotypes present in the 5 1 6
PKIS library, we confirmed that GW305074X (but not GW405841X) was also a low micromolar 5 1 7
HS2ST inhibitor, consistent with the broad sensitivity of HS2ST to this optimised class of RAF 5 1 8
inhibitor.
1 9
Although limited Structure Activity Relationships can be derived from our initial studies, these 5 2 0
findings demonstrate that HS2ST inhibitors can be discovered, and that several of these inhibitors for cell-based analysis. However, our discovery that oxindole-based RAF inhibitors are also HS2ST 5 2 6
inhibitors could provide new impetus for the design and synthesis of much more specific and potent 5 2 7
HS2ST inhibitors from this class of RAF kinase inhibitor. A requirement for rapid progress during 5 2 8 this process will be structure-based analysis of HS2ST in the presence of compounds, in order to 5 2 9
determine mechanism and mode(s) of interaction. Our initial docking studies suggest similar binding 5 3 0 modes for both rottlerin and the oxindole-based ligand GW407323A ( Figure 5) , with the potential for 5 3 1 cross-over between PAPS and substrate-binding sites present on the surface of HS2ST. It will be 5 3 2
intriguing to explore these binding modes by structural analysis and guided mutational approaches 5 3 3
[71], to evaluate potential drug-binding site residues in HS2ST and tease-apart requirements for 5 3 4 enzyme inhibition. It will also be important to evaluate whether compounds identified as in vitro 5 3 5
HS2ST inhibitors, including RAF inhibitors, can also interfere with HS sulphation and downstream 5 3 6 signalling in cells. Interestingly, suramin is a potent anti-angiogenic compound, and is reported to
have cellular effects on FGF signalling [72] , whereas aurintricarboxylate has multiple cellular effects 5 3 8
currently attributed to nucleotide-dependent processes; attempting to link some of these cellular phenotypes to the inhibition of glycan sulphation is also a worthy experimental strategy. Our work raises the possibility that HS2ST inhibitors could be strategically developed following the inhibition of sulphation has been stymied by a lack of tool compounds, which have the opportunity to 5 4 7 revolutionise cell biology when properly validated [73, 74] . We propose that if such compounds can Thermal denaturation profile of purified recombinant maltose binding protein (MBP). Experimental Supplementary Figure 8 A B
